The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Younossi, Zobair M.; Golabi, Pegah; Paik, James; Henry, Austin; Dongen, Catherine Van; Henry, Linda

doi:10.1097/hep.0000000000000004

Cited by 1,008 publications

(547 citation statements)

References 38 publications

Supporting

Mentioning

518

Contrasting

Unclassified

Order By: Relevance

“…NAFL is generally benign, whereas NASH can progress to cirrhosis, liver failure, and liver cancer. Globally, the estimated prevalence of NAFLD is 25.2%, whereas high-risk group patients, such as diabetic and obese, are 50% more prone to developing NAFLD [ 30 ]. Currently, there is no FDA-approved therapeutics available for NAFLD, although several classes of drugs for NAFLD/NASH treatment are under development, (i.e., FXR agonists and PPAR agonists) [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

et al. 2023

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease worldwide. Curcumin and andrographolide are famous for improving hepatic functions, being able to reverse oxidative stress and release pro-inflammatory cytokines, and they are implicated in hepatic stellate cell activation and in liver fibrosis development. Thus, we tested curcumin and andrographolide separately and in combination to determine their effect on triglyceride accumulation and ROS production, identifying the differential expression of genes involved in fatty liver and oxidative stress development. In vitro steatosis was induced in HepG2 cells and the protective effect of curcumin, andrographolide, and their combination was observed evaluating cell viability, lipid and triglyceride content, ROS levels, and microarray differential gene expression. Curcumin, andrographolide, and their association were effective in reducing steatosis, triglyceride content, and ROS stress, downregulating the genes involved in lipid accumulation. Moreover, the treatments were able to protect the cytotoxic effect of steatosis, promoting the expression of survival and anti-inflammatory genes. The present study showed that the association of curcumin and andrographolide could be used as a therapeutic approach to counter high lipid content and ROS levels in steatosis liver, avoiding the possible hepatotoxic effect of curcumin. Furthermore, this study improved our understanding of the antisteatosis and hepatoprotective properties of a curcumin and andrographolide combination.

show abstract

Section: Discussionmentioning

confidence: 99%

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

et al. 2023

View full text Add to dashboard Cite

show abstract

“…3 veranschaulicht die Verteilung der NAFLD in der mitteleuropäischen Gesamtbevölkerung. Neuere Meta-Analysen gehen sogar von einer weltweiten NAFLD-Prävalenz von 30 % aus [5].…”

Section: Epidemiologie Und Morbiditätunclassified

Adipositas und NAFLD: Assoziation oder Auslöser?

Roeb

Tacke

2023

Adipositas - Ursachen, Folgeerkrankungen, Therapie

View full text Add to dashboard Cite

ZusammenfassungDie nicht-alkoholische Fettlebererkrankung NAFLD wird als gravierendes Gesundheitsrisiko westlicher und auch kommender Industrienationen angesehen. Die Pathogenese der NAFLD und ihr Fortschreiten zu Fibrose und chronischen Lebererkrankungen ist teilweise noch unklar. Viele Studien zeigen, dass NAFLD mit einer erhöhten Insulinresistenz (IR) verbunden sein kann. IR, Fettleibigkeit, niedriges Adiponektin, (postprandiale) Dyslipidämie und Hyperglykämie sind die Hauptfaktoren, die zu NAFLD führen und den Verlauf sowie die Progression der Erkrankung beschleunigen. NAFLD kann Menschen jeden Alters betreffen und scheint bei verschiedenen ethnischen Gruppen unterschiedlich häufig zu sein. Umwelt- und Lebensstil-bedingte Faktoren wie reduzierte körperliche Aktivität und fettreiche Ernährung sind gut untersuchte Faktoren für die Entwicklung von IR-assoziierten Komorbiditäten und NAFLD. Jüngste Studien haben Fortschritte auf dem Gebiet der genetischen Risikofaktoren und Immunantwort in der NASH-Pathogenese gemacht. Eine Lebensstiländerung in Form von Gewichtsabnahme, Ernährungsumstellung und körperlicher Aktivität ist ein wichtiger Therapieansatz. Die medikamentöse Therapie orientiert sich - bei noch fehlender Zulassung spezifischer NAFLD Medikamente - an den Begleiterkrankungen (Fettstoffwechselstörungen, Adipositas, Diabetes) und dem Leberfibrosestadium. Bei ausgeprägter Adipositas können bariatrische Eingriffe zur Therapie von NAFLD und NASH durchgeführt werden. Gezielte Eingriffe in die zahlreichen Mechanismen, die am Fortschreiten von NASH beteiligt sind, sollen insbesondere die Entwicklung bzw. ein Fortschreiten der Leberfibrose verhindern.

show abstract

“…Non-alcoholic fatty liver disease (NAFLD) has reached a global prevalence of 30% and the increasing trend is ongoing ( 1 ). It involves a spectrum of diseases, including hepatic steatosis and non-alcoholic steatohepatitis (NASH) ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma

Jeong

Shin

2023

Front. Endocrinol.

View full text Add to dashboard Cite

The progression of non-alcoholic fatty liver disease (NAFLD), the most common liver disease, leads to non-alcoholic steatohepatitis and hepatocellular carcinoma. Despite the increasing incidence and prevalence of NAFLD, its therapeutic and preventive strategies to lower the disease burden is limited. In recent years, immunotherapy, including anti-programmed cell death 1/programmed cell death 1 ligand 1 treatment, has emerged as a potential approach to reach satisfactory modulation for the progression of NAFLD and treatment of NAFLD-related hepatocellular carcinoma. However, the effectiveness of immunotherapy against NAFLD and NAFLD-related hepatocellular carcinoma is in the early phase and it is yet not advanced. In addition, conflicting results are being reported regarding the prognosis of patients with NAFLD-related hepatocellular carcinoma and high expression of programmed cell death 1/programmed cell death 1 ligand 1. Herein, this review will discuss and elucidate the attempts and underlying mechanisms of immunotherapy against NAFLD and NAFLD-related hepatocellular carcinoma.

show abstract

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Cited by 1,008 publications

References 38 publications

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

Adipositas und NAFLD: Assoziation oder Auslöser?

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma

Contact Info

Product

Resources

About